Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,415 across all filing types
Latest filing 2013-11-14 Regulatory Filings
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release from Innate Pharma dated November 14, 2013, announcing that preclinical data on lirilumab will be presented at the upcoming ASH Annual Meeting. It details the content of the presentation (abstract highlights) and provides context on the drug and ongoing trials. This is a typical announcement regarding scientific data presentation, which falls under general corporate or investor communications. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a formal proxy/governance document, and it is an announcement about scientific progress rather than a formal regulatory filing fallback (RNS), the most appropriate category is Investor Presentation (IP) if it were the presentation itself, but since it is an *announcement* of data being presented, it aligns best with a general Investor Relations communication. However, given the specific definitions, this is a communication designed to inform investors about upcoming scientific milestones and data releases. It is not a formal 'Earnings Release' (ER) or a 'Management Discussion & Analysis' (MDA). It is an announcement of data that will be presented, which is often grouped with Investor Presentations or general news. Since it is a news release detailing scientific progress and upcoming presentation, and does not fit the other specific categories like DIV, CAP, or ER, it is best classified as a general Regulatory Filing (RNS) as a catch-all for non-standard announcements, or potentially an Investor Presentation (IP) if we interpret the announcement as preparatory material for investor consumption. Given the content is a press release announcing data presentation, RNS is the safest fallback for non-standard corporate news, but IP often covers scientific updates intended for investors. Since it is a press release announcing data that will be presented, and not the presentation itself, RNS is the most accurate fit for a general announcement not covered elsewhere.
2013-11-14 English
Ccommuniqué
Regulatory Filings Classification · 96% confidence The document is a press release dated November 14, 2013, from Innate Pharma SA. It announces that new preclinical data regarding their drug candidate, lirilumab, will be presented as a poster at the upcoming 55th annual meeting of the American Society of Hematology (ASH) in December 2013. The text details the scientific findings and mentions that the abstract for the poster is already online. Since the document's primary purpose is to announce the upcoming presentation of scientific data at a conference, it functions as an announcement of research findings rather than a full financial report (10-K, IR), a management discussion (MDA), or a formal earnings release (ER). It is a specific type of corporate communication related to R&D progress, which often falls under general Regulatory Filings (RNS) or Investor Presentations (IP) if it were the presentation itself. Given that it is an announcement about a poster presentation at a scientific congress, and not a comprehensive financial report or a formal regulatory filing like a 10-K or IR, the most fitting general category among the provided options is RNS (Regulatory Filings) as a catch-all for specific corporate updates that don't fit the financial reporting codes. However, since it is specifically about presenting research data, it is closely related to investor information. Since there is no specific code for 'Scientific Data Release Announcement', and it is not a full Investor Presentation (IP) but an announcement *about* a poster, RNS is the safest fallback. If we consider the content, it is an announcement of scientific progress, which is often shared with investors. Given the options, RNS is the most appropriate general regulatory/corporate announcement category for this type of non-financial, non-management specific update.
2013-11-14 French
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated November 8, 2013, announcing the selection and qualification of a drug candidate (IPH4102) for further development, including the plan to submit an Investigational New Drug (IND) application. It details scientific progress, collaboration, and mentions a poster presentation at a conference. This content is typical of an announcement regarding operational or clinical progress, which does not fit the specific categories like 10-K (Annual Report), ER (Earnings Release), or CT (Call Transcript). Since it is a general corporate announcement providing operational updates and is not a specific regulatory filing type listed (like DIRS, DIV, CAP, etc.), it falls best under the general Regulatory Filings/Announcements category, RNS, as a fallback for significant, non-standard corporate news releases.
2013-11-08 English
Communiqué IPH4102
Regulatory Filings Classification · 96% confidence The document is a press release dated November 8, 2013, announcing that Innate Pharma has selected and qualified the drug candidate IPH4102 for the start of regulatory preclinical development and plans to file for Phase I clinical trial authorization by the end of 2014. This is an announcement about a specific stage in drug development (preclinical/Phase I filing preparation) and is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). It is a specific corporate update related to R&D progress. Since there is no specific category for 'R&D Progress' or 'Clinical Trial Updates', and it is a formal announcement detailing corporate activity, it best fits the general 'Regulatory Filings' (RNS) category as a miscellaneous regulatory/corporate announcement, or potentially 'Capital/Financing Update' (CAP) if the context implied funding, but here it is purely operational/scientific progress. Given the options, RNS is the most appropriate fallback for a specific, non-financial, non-governance corporate update that doesn't fit the other specialized codes.
2013-11-08 French
131105_IPH_Chiffre_d_affaires_9_mois_2013
Earnings Release Classification · 98% confidence The document is titled with an announcement of revenue ('chiffre d'affaires') for the first nine months of 2013 and a treasury update. It provides specific financial figures (6.8 million euros in revenue, 24.9 million euros in cash) for a nine-month period ending September 30, 2013. This structure—a concise announcement of key financial results for a period shorter than a full year—is characteristic of an Earnings Release (ER). It is not a comprehensive report (like 10-K or IR), nor is it a transcript (CT) or a presentation (IP). It is the initial release of period results. 9M 2013
2013-11-05 French
Press release
Regulatory Filings Classification · 92% confidence The document is a press release dated October 15, 2013, announcing that Innate Pharma will present its proprietary Antibody-Drug Conjugate (ADC) technology at the World ADC Summit. It details the technology, includes quotes from the CEO, and provides links to the presentation and poster. This content is characteristic of an announcement intended to inform investors and the public about a scientific or business development, often preceding or accompanying a conference presentation. It is not a formal regulatory filing like a 10-K, a comprehensive quarterly report (IR), or a formal earnings release (ER). Since it is an announcement about company activities and technology updates aimed at investors, it best fits the Investor Presentation (IP) category, as it describes the content that would be presented, or potentially a Regulatory Filing (RNS) if it were a general announcement. Given the focus on presenting specific technical data and strategy to the investment community, 'Investor Presentation' (IP) is the most specific fit, even though it's the announcement *of* the presentation rather than the presentation slides themselves. However, since the document is short and serves primarily to disseminate news about a corporate event/update, and does not fit the strict definitions of ER, IR, or 10-K, it falls under general corporate communication. In the context of the provided definitions, it is a specific update on technology and business strategy, which aligns closely with the purpose of an Investor Presentation (IP). If it were purely a regulatory filing without specific investor focus, RNS would be used. Given the context of presenting technology at a summit, IP is chosen.
2013-10-15 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.